By Mill Chart
Last update: Jan 23, 2024
In this article we will dive into AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH) as a possible candidate for growth investing. Investors should always do their own research, but we noticed AMPHASTAR PHARMACEUTICALS IN showing up in our Louis Navellier growth screen, which makes it worth to investigate a bit more.
ChartMill assigns a proprietary Fundamental Rating to each stock. The score is computed daily by evaluating various fundamental indicators and properties. The score ranges from 0 to 10.
Overall AMPH gets a fundamental rating of 7 out of 10. We evaluated AMPH against 205 industry peers in the Pharmaceuticals industry. AMPH scores excellent on profitability, but there are some minor concerns on its financial health. AMPH is evaluated to be cheap and growing strongly. This does not happen too often! With these ratings, AMPH could be worth investigating further for value and growth investing!.
For an up to date full fundamental analysis you can check the fundamental report of AMPH
Our Lois Navellier screen will find you more ideas suited for growth investing.
This article should in no way be interpreted as advice in any way. The article is based on the observed metrics at the time of writing, but you should always make your own analysis and trade or invest at your own responsibility.
AMPHASTAR PHARMACEUTICALS IN
NASDAQ:AMPH (4/22/2024, 7:00:00 PM)
After market: 40.17 0 (0%)40.17
+0.16 (+0.4%)
Amphastar Pharmaceuticals reports Q4 financial results with a Non-GAAP EPS of $0.88, missing estimates by $0.03, while revenue of $178.1M beats expectations...
CRISPR Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating.
As the new business cycle gets started, here are some biotech stocks with potential that investors should pay attention to.
Axsome Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating.